Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B‐cell lymphoma

Cancer Science

Ukihide Tateishi⁶  Mitsuaki Tatsumi⁴  Takashi Terauchi¹  Kiyoshi Ando²  Nozomi Niitsu⁷  Won Seog Kim⁵  Cheolwon Suh⁸  Michinori Ogura³ 

[1] Division of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan;Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan;Department of Hematology and Oncology, Nagoya Daini Red Cross Center Hospital, Nagoya, Japan;Department of Radiology, Osaka University Graduate School of Medicine, Osaka, Japan;Hematology–Oncology, Samsung Medical Center, Seoul, Republic of Korea;Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan;Department of Hematology, Saitama Medical University International Medical Center, Saitama, Japan;Hematology–Oncology, Asan Medical Center, Seoul, Republic of Korea

关键词: [F‐18] fluorodeoxyglucose;    diffuse large B‐cell lymphoma;    lymphoma;    metabolic tumor burden;    positron emission tomography/computed tomography;   

DOI  :  10.1111/cas.12588

来源: Wiley

【 摘 要 】

Abstract

The aim of the present study was to investigate the feasibility of measuring metabolic tumor burden using [F-18] fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) treated with bendamustine–rituximab. Because the standardized uptake value is a critical parameter of tumor characterization, we carried out a phantom study of ¹⁸F-FDG PET/CT to ensure quality control for 28 machines in the 24 institutions (Japan, 17 institutions; Korea, 7 institutions) participating in our clinical study. Fifty-five patients with relapsed or refractory DLBCL were enrolled. The ¹⁸F-FDG PET/CT was acquired before treatment, after two cycles, and after the last treatment cycle. Treatment response was assessed after two cycles and after the last cycle using the Lugano classification. Using this classification, remission was complete in 15 patients (27%) and incomplete in 40 patients (73%) after two cycles of therapy, and remission was complete in 32 patients (58%) and incomplete in 23 patients (42%) after the last treatment cycle. The percentage change in all PET/CT parameters except for the area under the curve of the cumulative standardized uptake value–volume histogram was significantly greater in complete response patients than in non-complete response patients after two cycles and the last cycle. The Cox proportional hazard model and best subset selection method revealed that the percentage change of the sum of total lesion glycolysis after the last cycle (relative risk, 5.24; P = 0.003) was an independent predictor of progression-free survival. The percent change of sum of total lesion glycolysis, calculated from PET/CT, can be used to quantify the response to treatment and can predict progression-free survival after the last treatment cycle in patients with relapsed or refractory DLBCL treated with bendamustine–rituximab.

【 授权许可】

CC BY-NC-ND   
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.